BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8336751)

  • 1. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement.
    Turpie AG; Gent M; Laupacis A; Latour Y; Gunstensen J; Basile F; Klimek M; Hirsh J
    N Engl J Med; 1993 Aug; 329(8):524-9. PubMed ID: 8336751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
    Chimowitz MI; Lynn MJ; Howlett-Smith H; Stern BJ; Hertzberg VS; Frankel MR; Levine SR; Chaturvedi S; Kasner SE; Benesch CG; Sila CA; Jovin TG; Romano JG;
    N Engl J Med; 2005 Mar; 352(13):1305-16. PubMed ID: 15800226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.
    Mohr JP; Thompson JL; Lazar RM; Levin B; Sacco RL; Furie KL; Kistler JP; Albers GW; Pettigrew LC; Adams HP; Jackson CM; Pullicino P;
    N Engl J Med; 2001 Nov; 345(20):1444-51. PubMed ID: 11794192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.
    Ezekowitz MD; Bridgers SL; James KE; Carliner NH; Colling CL; Gornick CC; Krause-Steinrauf H; Kurtzke JF; Nazarian SM; Radford MJ
    N Engl J Med; 1992 Nov; 327(20):1406-12. PubMed ID: 1406859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
    Ridker PM; Goldhaber SZ; Danielson E; Rosenberg Y; Eby CS; Deitcher SR; Cushman M; Moll S; Kessler CM; Elliott CG; Paulson R; Wong T; Bauer KA; Schwartz BA; Miletich JP; Bounameaux H; Glynn RJ;
    N Engl J Med; 2003 Apr; 348(15):1425-34. PubMed ID: 12601075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
    Arch Intern Med; 1996 Feb; 156(4):409-16. PubMed ID: 8607726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP).
    Pengo V; Palareti G; Cucchini U; Molinatti M; Del Bono R; Baudo F; Ghirarduzzi A; Pegoraro C; Iliceto S;
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):241-8. PubMed ID: 17636186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of warfarin versus antiplatelet therapy in patients with a St. Jude Medical valve in the aortic position.
    Hartz RS; LoCicero J; Kucich V; DeBoer A; O'Mara S; Meyers SN; Michaelis LL
    J Thorac Cardiovasc Surg; 1986 Oct; 92(4):684-90. PubMed ID: 3762199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
    Kearon C; Gent M; Hirsh J; Weitz J; Kovacs MJ; Anderson DR; Turpie AG; Green D; Ginsberg JS; Wells P; MacKinnon B; Julian JA
    N Engl J Med; 1999 Mar; 340(12):901-7. PubMed ID: 10089183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.
    Pérez-Gómez F; Alegría E; Berjón J; Iriarte JA; Zumalde J; Salvador A; Mataix L;
    J Am Coll Cardiol; 2004 Oct; 44(8):1557-66. PubMed ID: 15489085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
    Yusuf S; Zhao F; Mehta SR; Chrolavicius S; Tognoni G; Fox KK;
    N Engl J Med; 2001 Aug; 345(7):494-502. PubMed ID: 11519503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis.
    Andersen LV; Vestergaard P; Deichgraeber P; Lindholt JS; Mortensen LS; Frost L
    Heart; 2008 Dec; 94(12):1607-13. PubMed ID: 18208828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose oral anticoagulation and antiplatelet therapy with St. Jude Medical heart valve prosthesis.
    Yamak B; Iscan Z; Mavitas B; Ulus AT; Katircioglu SF; Tasdemir O; Bayazit K
    J Heart Valve Dis; 1999 Nov; 8(6):665-73. PubMed ID: 10616246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
    Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late incidence and determinants of stroke after aortic and mitral valve replacement.
    Ruel M; Masters RG; Rubens FD; Bédard PJ; Pipe AL; Goldstein WG; Hendry PJ; Mesana TG
    Ann Thorac Surg; 2004 Jul; 78(1):77-83; discussion 83-4. PubMed ID: 15223407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Berger PB; Bhatt DL; Fuster V; Steg PG; Fox KA; Shao M; Brennan DM; Hacke W; Montalescot G; Steinhubl SR; Topol EJ;
    Circulation; 2010 Jun; 121(23):2575-83. PubMed ID: 20516378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors.
    Brueck M; Kramer W; Vogt P; Steinert N; Roth P; Görlach G; Schönburg M; Heidt MC
    Eur J Cardiothorac Surg; 2007 Jul; 32(1):108-12. PubMed ID: 17449264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.